Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
It would be a disruption of the societal pact we have had since 1962 that drugs will be studied to see if they work before they are marketed in the U.S., said Janet Woodcock, a former FDA acting commissioner
In recent years, the therapeutic footprint of this class has grown: long-acting agents (e.g., liraglutide, semaglutide) and next-generation dual/triple agonists (e.g., tirzepatide) have demonstrated superior glycemic control, weight reduction, and cardiovascular benefits in adults with T2DM (Yao et al., 2024)
Figure S19
Market size for GLP-1 receptor agonists is projected to reach USD 7.8 billion by 2036
US$ 21.84
US$ 27.63
US$ 22.91
US$ 25.28
